These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 9082652

  • 1. [Pathogenesis of multiple sclerosis: status of research].
    Hartung HP.
    Wien Med Wochenschr; 1996; 146(19-20):520-7. PubMed ID: 9082652
    [Abstract] [Full Text] [Related]

  • 2. Immunobiology of oligodendrocytes in multiple sclerosis.
    Ruffini F, Chojnacki A, Weiss S, Antel JP.
    Adv Neurol; 2006; 98():47-63. PubMed ID: 16400826
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis.
    Taoufik E, Tseveleki V, Euagelidou M, Emmanouil M, Voulgari-Kokota A, Haralambous S, Probert L.
    Neurodegener Dis; 2008; 5(1):32-7. PubMed ID: 18075273
    [Abstract] [Full Text] [Related]

  • 5. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis.
    Dhib-Jalbut S.
    Neurology; 2007 May 29; 68(22 Suppl 3):S13-21; discussion S43-54. PubMed ID: 17548563
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Autoreactive T lymphocytes in multiple sclerosis: pathogenic role and therapeutic targeting.
    Stinissen P, Raus J.
    Acta Neurol Belg; 1999 Mar 29; 99(1):65-9. PubMed ID: 10218096
    [Abstract] [Full Text] [Related]

  • 12. Immune-mediated demyelination.
    Hartung HP.
    Ann Neurol; 1993 Jun 29; 33(6):563-7. PubMed ID: 8498835
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity.
    Wiendl H, Feger U, Mittelbronn M, Jack C, Schreiner B, Stadelmann C, Antel J, Brueck W, Meyermann R, Bar-Or A, Kieseier BC, Weller M.
    Brain; 2005 Nov 29; 128(Pt 11):2689-704. PubMed ID: 16123145
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination.
    Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H.
    Ann Neurol; 1998 Apr 29; 43(4):465-71. PubMed ID: 9546327
    [Abstract] [Full Text] [Related]

  • 19. Effect of interferon gamma on T lymphocytes from patients with multiple sclerosis.
    Grimaldi LM, Martino G.
    Mult Scler; 1995 Apr 29; 1 Suppl 1():S38-43. PubMed ID: 9345397
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.